Physician profile
Sara Dean Castantini
NPI 1477929610
$3,590.17
in general payments reported to CMS, 2019-2025
37 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $974 · 2022: $1,177 · 2023: $415 · 2024: $685 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.86 | 2021-2025 | |
| Novo Nordisk INC | $423.40 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $318.82 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $254.09 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $218.37 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.79 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $189.55 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $145.02 | 2021-2022 | |
| Mylan Specialty L.P. | $142.39 | 2021-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $141.56 | 2021-2023 | Trintellix |
| Glaxosmithkline, LLC. | $95.46 | 2021-2023 | Trelegy Ellipta |
| Amgen INC. | $80.07 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.40 | 2022-2023 | |
| Corium, LLC | $60.86 | 2022-2024 | Azstarys |
| Ardelyx, INC. | $60.32 | 2024-2025 | Ibsrela |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Castantini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.